JP7661969B2 - １，４，５，６－テトラヒドロピリミジン－２－アミン誘導体 - Google Patents

１，４，５，６－テトラヒドロピリミジン－２－アミン誘導体 Download PDF

Info

Publication number
JP7661969B2
JP7661969B2 JP2022522202A JP2022522202A JP7661969B2 JP 7661969 B2 JP7661969 B2 JP 7661969B2 JP 2022522202 A JP2022522202 A JP 2022522202A JP 2022522202 A JP2022522202 A JP 2022522202A JP 7661969 B2 JP7661969 B2 JP 7661969B2
Authority
JP
Japan
Prior art keywords
group
fluoro
indazole
amino
tetrahydropyrimidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022522202A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021230325A1 (https=
Inventor
健一 小森
はるか 山田
速人 清水
康弘 阿賀
あゆみ 小川
道 長谷川
高志 松下
裕仁 ▲徳▼永
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ube Corp
Original Assignee
Ube Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ube Corp filed Critical Ube Corp
Publication of JPWO2021230325A1 publication Critical patent/JPWO2021230325A1/ja
Application granted granted Critical
Publication of JP7661969B2 publication Critical patent/JP7661969B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2022522202A 2020-05-14 2021-05-13 １，４，５，６－テトラヒドロピリミジン－２－アミン誘導体 Active JP7661969B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020085420 2020-05-14
JP2020085420 2020-05-14
PCT/JP2021/018252 WO2021230325A1 (ja) 2020-05-14 2021-05-13 １，４，５，６－テトラヒドロピリミジン－２－アミン誘導体

Publications (2)

Publication Number Publication Date
JPWO2021230325A1 JPWO2021230325A1 (https=) 2021-11-18
JP7661969B2 true JP7661969B2 (ja) 2025-04-15

Family

ID=78524455

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022522202A Active JP7661969B2 (ja) 2020-05-14 2021-05-13 １，４，５，６－テトラヒドロピリミジン－２－アミン誘導体

Country Status (10)

Country Link
US (1) US20230192661A1 (https=)
EP (1) EP4151632A4 (https=)
JP (1) JP7661969B2 (https=)
KR (1) KR20230011967A (https=)
CN (1) CN115551846B (https=)
AU (1) AU2021270095A1 (https=)
BR (1) BR112022023058A2 (https=)
CA (1) CA3182964A1 (https=)
MX (1) MX2022014200A (https=)
WO (1) WO2021230325A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023085396A1 (ja) * 2021-11-12 2023-05-19 Ｕｂｅ株式会社 アルポート症候群を治療または予防するための医薬組成物
EP4733297A1 (en) * 2023-06-22 2026-04-29 Antibody Therapeutics, Inc. Integrin-inhibiting small molecule compound

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997008145A1 (en) 1995-08-30 1997-03-06 G.D. Searle & Co. Meta-guanidine, urea, thiourea or azacyclic amino benzoic acid derivatives as integrin antagonists
JP2002511462A (ja) 1998-04-10 2002-04-16 ジー・ディー・サール・アンド・カンパニー ビトロネクチンアンタゴニストとしてのヘテロ環式グリシルβ−アラニン誘導体
JP2006514050A (ja) 2002-12-20 2006-04-27 ファルマシア・コーポレーション インテグリン受容体アンタゴニスト誘導体としてのβ−アミノ酸化合物のＲ異性体
JP2015524412A (ja) 2012-07-18 2015-08-24 セントルイス ユニバーシティ インテグリンアンタゴニストとしてのβアミノ酸誘導体
JP2019500355A (ja) 2015-12-30 2019-01-10 セントルイス ユニバーシティ 汎インテグリンアンタゴニストとしてのメタ−アザ環式アミノ安息香酸誘導体

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA994406B (en) 1998-03-04 2000-02-11 Searle & Co Meta-azacyclic amino benzoic acid and derivatives thereof.
US6372719B1 (en) 1998-03-04 2002-04-16 Jay Cunningham ανβ3 integrin antagonists in combination with chemotherapeutic agents
US8716226B2 (en) 2012-07-18 2014-05-06 Saint Louis University 3,5 phenyl-substituted beta amino acid derivatives as integrin antagonists

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997008145A1 (en) 1995-08-30 1997-03-06 G.D. Searle & Co. Meta-guanidine, urea, thiourea or azacyclic amino benzoic acid derivatives as integrin antagonists
JP2002511462A (ja) 1998-04-10 2002-04-16 ジー・ディー・サール・アンド・カンパニー ビトロネクチンアンタゴニストとしてのヘテロ環式グリシルβ−アラニン誘導体
JP2006514050A (ja) 2002-12-20 2006-04-27 ファルマシア・コーポレーション インテグリン受容体アンタゴニスト誘導体としてのβ−アミノ酸化合物のＲ異性体
JP2015524412A (ja) 2012-07-18 2015-08-24 セントルイス ユニバーシティ インテグリンアンタゴニストとしてのβアミノ酸誘導体
JP2019500355A (ja) 2015-12-30 2019-01-10 セントルイス ユニバーシティ 汎インテグリンアンタゴニストとしてのメタ−アザ環式アミノ安息香酸誘導体

Also Published As

Publication number Publication date
CN115551846B (zh) 2024-03-08
EP4151632A4 (en) 2024-04-24
CA3182964A1 (en) 2021-11-18
AU2021270095A1 (en) 2022-12-22
JPWO2021230325A1 (https=) 2021-11-18
EP4151632A1 (en) 2023-03-22
WO2021230325A1 (ja) 2021-11-18
MX2022014200A (es) 2022-12-07
US20230192661A1 (en) 2023-06-22
KR20230011967A (ko) 2023-01-25
BR112022023058A2 (pt) 2022-12-20
CN115551846A (zh) 2022-12-30

Similar Documents

Publication Publication Date Title
JP7767492B2 (ja) Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物
JP7602573B2 (ja) Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体
CN104352492B (zh) 以芳基磺酰基衍生物作为有效成分的长链脂肪酸延长酶抑制剂
IL271117A (en) Diazabicyclic substituted imidazopyrimidines and their use for the treatment of breathing disorders
CN104822680A (zh) 咪唑并吡啶化合物
CN104066729A (zh) 溶血磷脂酸受体拮抗剂
TWI483727B (zh) 瑞巴派特前體藥物、其製造方法及其運用
JPWO2008123207A1 (ja) オルニチン誘導体
CN116354933B (zh) 作为雄激素受体调节剂的杂环化合物及其应用
JP7661969B2 (ja) １，４，５，６－テトラヒドロピリミジン－２－アミン誘導体
JP2022521081A (ja) Ｈｂｖ感染若しくはｈｂｖ誘導性疾患の治療において有用なアミド誘導体
WO2021097117A2 (en) Novel functionalized lactones as modulators of the 5-hydroxytryptamine receptor 7 and their method of use
WO2023085396A1 (ja) アルポート症候群を治療または予防するための医薬組成物
CN107849018B (zh) 哌嗪衍生物
KR20130141554A (ko) 신규한 항암제
RU2845863C1 (ru) Производное 1,4,5,6-тетрагидропиримидин-2-амина
CN109422751B (zh) 一类具有降解酪氨酸蛋白激酶jak3活性的化合物
JP2023002841A (ja) 高血圧症及び／又は線維症を処置するための組成物
CN114585603B (zh) 前列腺素ep4受体拮抗剂化合物
WO2023277116A1 (ja) アミノシクロヘキサン誘導体及びその医薬用途
AU2003221394B2 (en) Novel pyridone derivative

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221201

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240315

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250214

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250304

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250317

R150 Certificate of patent or registration of utility model

Ref document number: 7661969

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150